Driven by science and passionate about advancing patient care, DynamiCure is translating potentially revolutionizing new insights on immuno-normalization into a pipeline of innovative antibody candidates with first-in-class and best-in-class potential. We are a team with broad and deep industry experience rapidly advancing multiple candidates towards the clinic.
Our lead program, DC-6001, aims to address the current limitations of today’s most advanced cancer treatments by interfering with the CD93 pathway, a novel mechanism demonstrated to normalize malignant tumor vasculature. By binding to different epitopes of the CD93 receptor, we believe our development candidates have the potential to turn the tumor microenvironment (TME) from immunosuppressive to immunostimulatory and to become necessary pieces of the combinatorial therapy puzzle across a broad range of tumor types.
The DC-6001 program consists of two anti-CD93 monoclonal antibodies (DCBY02 and DCSZ11), each of which has demonstrated distinct in vitro and in vivo properties and anti-tumor activity in pre-clinical development. We are currently enrolling participants with a wide range of advanced cancers in a Phase 1 clinical trial (NCT05496595) evaluating the safety and anti-tumor activity of DCBY02; we expect to launch a parallel study of DCSZ11 in early 2023.
As we explore additional targets, technologies, and mechanisms, we are inspired by patients with unmet medical needs, each other, and our partners, united in our goal to provide patients worldwide with access to our innovations.
DynamiCure is headquartered in Waltham, Massachusetts.
Our logo comes from the Classic of Mountains and Seas, China’s oldest classic text, and represents the divine creature Dangkang, a creature thought to bring bountiful harvests, good fortune, and vigor, representing health, vitality, and endless energy.
Our name DynamiCure reflects both our dynamic state of activity – energetic and continuously evolving – and our mission to cure disease.
Our Values.
Empathy
Passionate about advancing patient care, we are united in our goal to provide worldwide access to impactful new treatment options
Dedication
Driven by science and constant learning, we relentlessly pursue excellence
Collaboration
Believing we are stronger together, we complement and challenge each other and our partners to surpass expectations
Transparency
With trust and respect, we encourage the free exchange of ideas and open communication
Our Values.
Empathy
Passionate about advancing patient care, we are united in our goal to provide worldwide access to impactful new treatment options
Dedication
Driven by science and constant learning, we relentlessly pursue excellence
Collaboration
Believing we are stronger together, we complement and challenge each other and our partners to surpass expectations
Transparency
With trust and respect, we encourage the free exchange of ideas and open communication
Our Leadership
Igor Proscurshim
Vice President, Global Clinical Development
×
Igor Proscurshim
Igor Proscurshim, M.D., a surgeon by training, brings more than 10 years of experience in clinical research and oncology drug development. Drug development offers the opportunity to make a significant impact in thousands of patients lives which is what motivated his transition from surgery. Prior to becoming Head of Clinical Development at DynamiCure, Dr. Proscurshim led clinical development at Ichnos Sciences and led clinical development of immune-oncology assets at Takeda Pharmaceuticals. He began his industry career at Recepta Biopharma, a small biotech spin-out of Ludwig Cancer Research based in Brazil and moved to the United States to lead clinical studies at Agenus with their acquisition of the immune-oncology portfolio. Dr. Proscurshim received a B.S. in biology from Baylor University and an M.D. from the University of São Paulo where he also completed his surgical training.
Scientific Collaborators
Our scientist founder, Dr. Lieping Chen, is a world-renowned immunologist and oncologist. His pioneering work paved the way for cancer immunotherapy with landmark studies uncovering the immunosuppressive role of the PD-1/PD-L1 pathway in the tumor microenvironment and laying the foundation for translational research in cancer immunotherapy. Dr. Chen is the United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, Dermatology, and Medicine (Medical Oncology) at Yale University. He is also a Co-Leader of the Cancer Immunology Program at Yale Cancer Center. He was elected to the Academia Sinica of Taiwan, China, and is a member of the US National Academy of Sciences. Dr. Chen was recognized as the #1 Breakthrough Scientist of the Year by Science in 2013, was presented with the William B. Coley Award, the top prize in immunology research, in 2014, received the Steinman Award of the American Association of Immunologists in 2016, and received the Warren Alpert Foundation Prize in 2017.
Dr. Lieping Chen
Dr. Yuwen ZhuYuwen Zhu, PhD, is currently an Associate Professor of Surgical Oncology in the Department of Surgery at the University of Colorado Anschutz Medical Campus (CU AMC) following extensive work performed in laboratories studying cancer immunotherapy at Johns Hopkins Medical and Yale University. His research focuses on ways to normalize tumor vasculature, improving pathways to the tumor so drugs and the body’s immune system can better reach and attack the disease.
DynamiCure has obtained worldwide exclusive commercial licenses from Yale University and the University of Colorado for several novel targets resulting from the research of Drs. Chen and Zhu and we continue to collaborate with both laboratories on additional research programs.